ALLMedicine™ Gastrointestinal Cancers Center
Research & Reviews 881 results
https://doi.org/10.1016/j.hpb.2022.04.009
HPB : the Official Journal of the International Hepato Pa... Meyer YM, Galjart B et. al.
May 14th, 2022 - Sarcopenia is associated with impaired short- and long-term outcomes in gastrointestinal cancers. Whether sarcopenia is associated with impaired survival after local therapy of Colorectal Cancer Liver Metastases (CRLM) remains controversial. This ...
https://doi.org/10.1016/j.orcp.2022.05.002
Obesity Research & Clinical Practice; Cossu ML, Fancellu A et. al.
May 14th, 2022 - The effects of bariatric surgery on the development of gastrointestinal cancers remain ill defined. We present a case of jejunal adenocarcinoma developing 19 years after biliopancreatic diversion (BPD) procedure according to Scopinaro's technique....
https://clinicaltrials.gov/ct2/show/NCT01313442
May 13th, 2022 - BACKGROUND: Numerous recent therapeutic advances have changed standard treatment options for patients with GI cancer. These include newer chemotherapeutic agents in addition to established proof of principle for anti-angiogenic agents. The burden ...
https://clinicaltrials.gov/ct2/show/NCT03929666
May 11th, 2022 - Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the r...
https://doi.org/10.1038/s41591-022-01800-8 10.1056/NEJMoa1709866 10.1056/NEJMc1800913 10.1056/NEJMoa1804980 10.1056/NEJMoa2024850 10.1158/1078-0432.CCR-17-0432 10.1146/annurev-med-062315-120245 10.1016/j.ccell.2020.07.005 10.1186/s13287-020-02128-1 10.1093/annonc/mdz199 10.1016/j.annonc.2021.02.005 10.1093/jnci/djy134 10.1016/j.bbmt.2018.12.758 10.1182/blood-2019-129624 10.1016/S0140-6736(17)31827-5 10.1001/jamaoncol.2018.0013 10.1016/S1470-2045(18)30739-3 10.1200/JCO.2015.63.5995 10.1097/SLA.0000000000002040 10.3748/wjg.v21.i40.11428 10.3390/jcm10214882 10.1186/s12885-021-09027-5 10.1016/S1470-2045(03)01074-X 10.1186/s12943-018-0928-4 10.1038/cmi.2014.104 10.1016/j.coi.2007.04.012 10.1038/bjc.2013.415 10.1007/s13238-017-0440-4 10.1016/j.jcyt.2020.04.088 10.3109/1547691X.2011.642418 10.1200/JCO.2011.36.5742 10.1111/cas.12419 10.3389/fonc.2019.01237 10.1007/s11864-020-0706-6 10.1016/j.ymthe.2016.10.020 10.5858/arpa.2014-0074-RA 10.5858/arpa.2013-0610-CP 10.4155/bio-2020-0221 10.4155/bio-2021-0007
Nature Medicine; Qi C, Gong J et. al.
May 10th, 2022 - Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR T cells showed promising efficacy against gastric cancer...
Guidelines 2 results
https://doi.org/10.1053/j.gastro.2021.08.058
Gastroenterology Wang AY, Hwang JH et. al.
Oct 26th, 2021 - The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update was to review the available evidence and provide expert advice regarding surveillance using endoscopy and other relevant modalities after removal...
https://doi.org/10.1016/j.ejca.2018.09.004
European Journal of Cancer (Oxford, England : 1990); Vangala DB, Cauchin E et. al.
Oct 21st, 2018 - Patients with hereditary gastrointestinal (GI) cancers represent a substantial fraction of the overall affected population. Although awareness for hereditary GI cancer syndromes is on the rise, identification of patients and measures of surveillan...
Drugs 1 results see all →
Clinicaltrials.gov 21 results
https://clinicaltrials.gov/ct2/show/NCT01313442
May 13th, 2022 - BACKGROUND: Numerous recent therapeutic advances have changed standard treatment options for patients with GI cancer. These include newer chemotherapeutic agents in addition to established proof of principle for anti-angiogenic agents. The burden ...
https://clinicaltrials.gov/ct2/show/NCT03929666
May 11th, 2022 - Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the r...
https://clinicaltrials.gov/ct2/show/NCT03693677
Mar 24th, 2022 - Pancreatic cancer (PC) is the seventh cause from cancer and the fifth cause from cancer-related death in Europe. Nearly as many deaths occur from PC than the number of new cases diagnosed each year, reflecting the poor prognosis typically associat...
https://clinicaltrials.gov/ct2/show/NCT01445327
Feb 1st, 2022 - Background: Gastrointestinal (GI) carcinomas represent one of the most commonly diagnosed malignancies in the United States. A sensitive and specific marker of tumor persistence or recurrence would permit a more accurate determination of the appro...
https://clinicaltrials.gov/ct2/show/NCT02853474
Dec 21st, 2021 - Medical oncology is aimed to increase patient's survival, even at metastatic stages, in addition to disease-related and treatment-related symptoms. However, providing palliative care (PC) which includes symptoms management, nutritional support, ps...
News 556 results
https://www.onclive.com/view/bi-836880-ezabenlimab-combo-had-limited-antitumor-activity-but-manageable-safety-in-advanced-mss-crc
May 2nd, 2022 - The VEGF/Ang2–targeting bispecific nanobody BI 836880, in combination with ezabenlimab (BI 754091), produced antitumor activity found to be comparable to that of available third-line therapy options in patients with advanced microsatellite stable ...
https://www.medscape.com/viewarticle/972445
Apr 20th, 2022 - Clinicians are struggling to make sense of conflicting regulations from the Food and Drug Administration and the European Medicines Agency on whether measuring programmed death–ligand 1 (PD-L1) is essential before prescribing checkpoint inhibitors...
https://www.mdedge.com/hematology-oncology/article/253873/gastrointestinal-cancer/pd-l1-test-debated-gastroesophageal
Laird Harrison
Apr 19th, 2022 - Clinicians are struggling to make sense of conflicting regulations from the Food and Drug Administration and the European Medicines Agency on whether measuring programmed death–ligand 1 (PD-L1) is essential before prescribing checkpoint inhibitors.
https://www.onclive.com/view/nivolumab-ipilimumab-approved-in-europe-for-frontline-pd-l1-advanced-escc
Apr 5th, 2022 - The European Commission has approved the dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for use in the frontline treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell...
https://www.medscape.com/viewarticle/971119
Mar 29th, 2022 - The 5 days that she spent at her mother's bedside were eye-opening for an oncologist used to being on the other side of the clinician–patient relationship. "As a physician, I thought I had a unique perspective of things that were done well — and t...
